CETUXIMAB AND FOLFIRI AS FIRST-LINE TREATMENT OF LOCALLY ADVANCED AND METASTATIC GASTRIC CANCER

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004072-37-IT

Enrollment

Registered

2006-04-21

Start date

2004-09-09

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced or metastatic non-resectable gastric cancer stomach or gastro-esophageal junction MedDRA version: 6.1 Level: PT Classification code 10017758

Interventions

Trade Name: Erbitux Pharmaceutical Form: Solution for infusion Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: CITOFOLIN 15MG IM IV 6F 6 F Pharmac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026